Actively Recruiting

Age: 18Years +
All Genders
NCT06782971

Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX

Led by Clinical Hub for Interventional Research (CHOIR) · Updated on 2025-12-08

25

Participants Needed

4

Research Sites

247 weeks

Total Duration

On this page

Sponsors

C

Clinical Hub for Interventional Research (CHOIR)

Lead Sponsor

C

Cancer Institute NSW

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this observational study is to develop new ways to test new drug combinations to kill tumour cells, in patients with acute myeloid leukemia (AML). The main questions it aims to answer are: * Are there new ways to speed up discovery of better treatments for AML patients using AML cells from individual from patients in special mice that can accept human tissue? * Do these mice show treatment responses that are similar to the individual AML patient from whom cells were derived? Participants with AML who are taking standard of care treatment of venetoclax and azacitidine will be asked to donate blood and bone marrow samples for this study.

CONDITIONS

Official Title

Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years and above
  • Patients with suspicion of AML requiring screening procedures
  • Documented diagnosis of AML by WHO Classification and/or International Consensus Classification
  • Includes all AML subtypes regardless of prior therapies or transplant eligibility
  • Concurrent participation in other clinical trials allowed
  • Documented myeloblast percentage 20% or more in bone marrow or blood within 12 weeks of treatment start
  • Planned to begin venetoclax and azacitidine therapy
  • Provided written informed consent before any study procedures
Not Eligible

You will not qualify if you...

  • Any condition that may compromise patient safety, study data quality, or adherence to study procedures as assessed by the Investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Canberra Health Services

Canberra, Australian Capital Territory, Australia, 2605

Actively Recruiting

2

Prince of Wales Hospital

Sydney, New South Wales, Australia, 2031

Actively Recruiting

3

Royal North Shore Hospital

Sydney, New South Wales, Australia, 2065

Not Yet Recruiting

4

Westmead Hospital

Westmead, New South Wales, Australia, 2145

Actively Recruiting

Loading map...

Research Team

J

John Pimanda, Professor

CONTACT

M

Mark Polizzotto, Professor

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here